Ardelyx, Inc.
Company Overview
Overall Headcount Trend
Overall Headcount Trend
Company growth over the last 12 months
Salaries
Job Posting Salary Data
From 2 marketing roles posted in the last 12 months
Community Salary Data
Help build salary transparency at Ardelyx, Inc.. Share your compensation anonymously.
Reviews
Jobs
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. The company is developing RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Community Guidelines: https://rb.gy/07ltg3
Company Information
- Company Type
- In-House Team
- Company Size
- Founded
- 2007
- Headquarters
- Waltham
Why Work at Ardelyx, Inc.?
Discover what makes Ardelyx, Inc. a great place to build your marketing career. View salary data, benefits, and employee insights on the other tabs.
